Delving into the Latest Updates on Beijing Medisai Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Bcr-Abl(Bcr-Abl tyrosine kinase)	1

The main purpose of this study is to investigate the tolerability and safety of a single oral administration of Meditinib sulfate tablets in subjects with newly diagnosed chronic myeloid leukemia in the chronic phase; the secondary purpose is to investigate the human pharmacokinetic characteristics of a single oral administration of Meditinib sulfate tablets in subjects with newly diagnosed chronic myeloid leukemia in the chronic phase.

Start Date08 Sep 2016

Sponsor / Collaborator

Beijing Meidi Kangxin Pharmaceutical Technology Co.,Ltd.

[+2]

100 Clinical Results associated with Beijing Medisai Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Medisai Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Medisai Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Medisai Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data